BioCentury | May 28, 2020
Finance

argenx parlays myasthenia gravis data into year’s second-largest follow-on at $750M

In the year’s second-largest follow-on to date, argenx raised $750 million through the sale of 2.6 million ADSs at $205 and 1.1 million shares at €186.52 ($205.25). The price is a 3% discount to the...
BioCentury | May 27, 2020
Product Development

argenx data put myasthenia gravis therapy a step closer to challenging Soliris, raising year’s second-biggest follow-on

Armed with pivotal data showing efficacy for its myasthenia gravis candidate, argenx plans to submit a BLA by year-end for efgartigimod. If approved, it would provide patients with an alternative mechanism to that of Alexion’s...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

A comparison of therapies that have shown promise, or failed to do so, in myasthenia gravis suggests targeting production of autoantibodies may be a less fruitful approach than blocking the effects of the autoantibodies or...
BC Week In Review | Feb 8, 2019
Company News

Halozyme grants argenx access to Enhanze subcutaneous delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted argenx S.E. (NASDAQ:ARGX) exclusive rights to use Halozyme's Enhanze subcutaneous drug delivery technology in combination with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod...
BC Innovations | Jan 24, 2019
Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
BC Week In Review | Dec 7, 2018
Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
BC Extra | Dec 4, 2018
Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
BC Extra | Nov 1, 2018
Clinical News

argenx's CD70 mAb leads to 92% response rate in AML

In an abstract released ahead of next month’s American Society of Hematology meeting, argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said cusatuzumab (ARGX-110) plus Vidaza azacitidine led to an overall response rate (ORR) of 92% in the Phase...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Sep 28, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...
Items per page:
1 - 10 of 35